• Je něco špatně v tomto záznamu ?

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia

P. Janovska, L. Poppova, K. Plevova, H. Plesingerova, M. Behal, M. Kaucka, P. Ovesna, M. Hlozkova, M. Borsky, O. Stehlikova, Y. Brychtova, M. Doubek, M. Machalova, S. Baskar, A. Kozubik, S. Pospisilova, S. Pavlova, V. Bryja,

. 2016 ; 22 (2) : 459-469. [pub] 20150803

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Intramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17001069

Grantová podpora
NT11217 MZ0 CEP - Centrální evidence projektů
NV15-29793A MZ0 CEP - Centrální evidence projektů

PURPOSE: ROR1, a receptor in the noncanonical Wnt/planar cell polarity (PCP) pathway, is upregulated in malignant B cells of chronic lymphocytic leukemia (CLL) patients. It has been shown that the Wnt/PCP pathway drives pathogenesis of CLL, but which factors activate the ROR1 and PCP pathway in CLL cells remains unclear. EXPERIMENTAL DESIGN: B lymphocytes from the peripheral blood of CLL patients were negatively separated using RosetteSep (StemCell) and gradient density centrifugation. Relative expression of WNT5A, WNT5B, and ROR1 was assessed by quantitative real-time PCR. Protein levels, protein interaction, and downstream signaling were analyzed by immunoprecipitation and Western blotting. Migration capacity of primary CLL cells was analyzed by the Transwell migration assay. RESULTS: By analyzing the expression in 137 previously untreated CLL patients, we demonstrate that WNT5A and WNT5B genes show dramatically (five orders of magnitude) varying expression in CLL cells. High WNT5A and WNT5B expression strongly associates with unmutated IGHV and shortened time to first treatment. In addition, WNT5A levels associate, independent of IGHV status, with the clinically worst CLL subgroups characterized by dysfunctional p53 and mutated SF3B1. We provide functional evidence that WNT5A-positive primary CLL cells have increased motility and attenuated chemotaxis toward CXCL12 and CCL19 that can be overcome by inhibitors of Wnt/PCP signaling. CONCLUSIONS: These observations identify Wnt-5a as the crucial regulator of ROR1 activity in CLL and suggest that the autocrine Wnt-5a signaling pathway allows CLL cells to overcome natural microenvironmental regulation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001069
003      
CZ-PrNML
005      
20201031182058.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-15-0154 $2 doi
024    7_
$a 10.1158/1078-0432.CCR-15-0154 $2 doi
035    __
$a (PubMed)26240275
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Janovská, Pavlína $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. $7 mub20211103818
245    10
$a Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia / $c P. Janovska, L. Poppova, K. Plevova, H. Plesingerova, M. Behal, M. Kaucka, P. Ovesna, M. Hlozkova, M. Borsky, O. Stehlikova, Y. Brychtova, M. Doubek, M. Machalova, S. Baskar, A. Kozubik, S. Pospisilova, S. Pavlova, V. Bryja,
520    9_
$a PURPOSE: ROR1, a receptor in the noncanonical Wnt/planar cell polarity (PCP) pathway, is upregulated in malignant B cells of chronic lymphocytic leukemia (CLL) patients. It has been shown that the Wnt/PCP pathway drives pathogenesis of CLL, but which factors activate the ROR1 and PCP pathway in CLL cells remains unclear. EXPERIMENTAL DESIGN: B lymphocytes from the peripheral blood of CLL patients were negatively separated using RosetteSep (StemCell) and gradient density centrifugation. Relative expression of WNT5A, WNT5B, and ROR1 was assessed by quantitative real-time PCR. Protein levels, protein interaction, and downstream signaling were analyzed by immunoprecipitation and Western blotting. Migration capacity of primary CLL cells was analyzed by the Transwell migration assay. RESULTS: By analyzing the expression in 137 previously untreated CLL patients, we demonstrate that WNT5A and WNT5B genes show dramatically (five orders of magnitude) varying expression in CLL cells. High WNT5A and WNT5B expression strongly associates with unmutated IGHV and shortened time to first treatment. In addition, WNT5A levels associate, independent of IGHV status, with the clinically worst CLL subgroups characterized by dysfunctional p53 and mutated SF3B1. We provide functional evidence that WNT5A-positive primary CLL cells have increased motility and attenuated chemotaxis toward CXCL12 and CCL19 that can be overcome by inhibitors of Wnt/PCP signaling. CONCLUSIONS: These observations identify Wnt-5a as the crucial regulator of ROR1 activity in CLL and suggest that the autocrine Wnt-5a signaling pathway allows CLL cells to overcome natural microenvironmental regulation.
650    _2
$a autokrinní signalizace $x fyziologie $7 D019898
650    _2
$a B-lymfocyty $x metabolismus $7 D001402
650    _2
$a pohyb buněk $x fyziologie $7 D002465
650    _2
$a chemotaxe $x fyziologie $7 D002633
650    _2
$a regulace genové exprese u nádorů $x fyziologie $7 D015972
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x metabolismus $7 D015451
650    _2
$a protoonkogenní proteiny $x metabolismus $7 D011518
650    _2
$a sirotčí receptory podobné receptoru tyrosinkinasy $x metabolismus $7 D057050
650    _2
$a upregulace $x fyziologie $7 D015854
650    _2
$a proteiny Wnt $x metabolismus $7 D051153
650    _2
$a signální dráha Wnt $x fyziologie $7 D060449
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poppová, Lucie $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 _AN091214
700    1_
$a Plevová, Karla $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0158852
700    1_
$a Plešingerová, Hana $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Běhal, Martin $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Kaucká, Markéta $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. $7 _AN068807
700    1_
$a Ovesná, Petra, $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. $d 1982- $7 mub2013761100
700    1_
$a Hložková, Michaela $u CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 _AN091215
700    1_
$a Borský, Marek $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. $7 xx0185903
700    1_
$a Stehlíková, Olga $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. $7 _AN091216
700    1_
$a Brychtová, Yvona $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. $7 xx0105542
700    1_
$a Doubek, Michael, $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $d 1972- $7 mzk2004217554
700    1_
$a Machalova, Michaela $u Department of Paediatric Otorhinolaryngology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Baskar, Sivasubramanian $u Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.
700    1_
$a Kozubík, Alois, $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic. $d 1958- $7 mzk2004237023
700    1_
$a Pospíšilová, Šárka, $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $d 1969- $7 xx0101843
700    1_
$a Pavlová, Šárka $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0117816
700    1_
$a Bryja, Vítězslav, $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic. bryja@sci.muni.cz. $d 1977- $7 xx0035073
773    0_
$w MED00001121 $t Clinical cancer research an official journal of the American Association for Cancer Research $x 1078-0432 $g Roč. 22, č. 2 (2016), s. 459-469
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26240275 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20201031182058 $b ABA008
999    __
$a ok $b bmc $g 1180209 $s 961636
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 2 $d 459-469 $e 20150803 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
GRA    __
$a NT11217 $p MZ0
GRA    __
$a NV15-29793A $p MZ0
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace